These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 10939604)
1. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody. Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A Tumori; 2000; 86(3):229-32. PubMed ID: 10939604 [TBL] [Abstract][Full Text] [Related]
2. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Maira G J Clin Pathol; 1999 Feb; 52(2):107-11. PubMed ID: 10396237 [TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. Mastronardi L; Guiducci A; Puzzilli F BMC Cancer; 2001; 1():12. PubMed ID: 11570981 [TBL] [Abstract][Full Text] [Related]
4. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Pizarro CB; Oliveira MC; Coutinho LB; Ferreira NP Braz J Med Biol Res; 2004 Feb; 37(2):235-43. PubMed ID: 14762579 [TBL] [Abstract][Full Text] [Related]
5. Anterior pituitary adenomas in patients aged more than 65 years: analysis of growth fraction (using the MIB-1 monoclonal antibody) and of clinical features in comparison to younger patients. Mastronardi L; Guiducci A; Puzzilli F; Maira G Clin Neurol Neurosurg; 2002 Jan; 104(1):44-8. PubMed ID: 11792476 [TBL] [Abstract][Full Text] [Related]
6. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Jaffrain-Rea ML; Di Stefano D; Minniti G; Esposito V; Bultrini A; Ferretti E; Santoro A; Faticanti Scucchi L; Gulino A; Cantore G Endocr Relat Cancer; 2002 Jun; 9(2):103-13. PubMed ID: 12121834 [TBL] [Abstract][Full Text] [Related]
8. Relationships among DNA Index, S-Phase, and invasive behavior in anterior pituitary adenomas. A cytometric study of 61 cases with Feulgen-positive DNA analysis. Mastronardi L; Guiducci A; Buttaro FM; Cristallini EG; Puzzilli F; Maira G Surg Neurol; 2001 Jul; 56(1):27-32. PubMed ID: 11546567 [TBL] [Abstract][Full Text] [Related]
9. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912 [TBL] [Abstract][Full Text] [Related]
10. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness. Shimon I; Hinton DR; Weiss MH; Melmed S Clin Endocrinol (Oxf); 1998 Jan; 48(1):23-9. PubMed ID: 9509064 [TBL] [Abstract][Full Text] [Related]
11. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025 [TBL] [Abstract][Full Text] [Related]
12. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of RCAS1 in human pituitary adenomas. Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045 [TBL] [Abstract][Full Text] [Related]
14. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Righi A; Morandi L; Leonardi E; Farnedi A; Marucci G; Sisto A; Frank G; Faustini-Fustini M; Zoli M; Mazzatenta D; Agati R; Foschini MP Hum Pathol; 2013 Nov; 44(11):2400-9. PubMed ID: 24007691 [TBL] [Abstract][Full Text] [Related]
15. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Thapar K; Kovacs K; Scheithauer BW; Stefaneanu L; Horvath E; Pernicone PJ; Murray D; Laws ER Neurosurgery; 1996 Jan; 38(1):99-106; discussion 106-7. PubMed ID: 8747957 [TBL] [Abstract][Full Text] [Related]
16. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744 [TBL] [Abstract][Full Text] [Related]
18. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390 [TBL] [Abstract][Full Text] [Related]
19. The Clinical Utility of TIMP3 Expression in ACTH-Secreting Pituitary Tumor. Sun B; Liu X; Yang Y; Dai C; Li Y; Jiao Y; Wei Z; Yao Y; Feng M; Bao X; Deng K; Wang N; Wang R J Mol Neurosci; 2016 Jan; 58(1):137-44. PubMed ID: 26676407 [TBL] [Abstract][Full Text] [Related]